Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Today presentation: BIO International Convention
The Brewer Group, Brewer and Associates Consulting, LLC (B&A) provides tailored global business development and marketing support for small-cap and middle market companies enabling them to develop innovative strategies, enhance brand recognition, and gain worldwide prominence. Our seasoned and ever-expanding business development team works hands-on with clients across a wide variety of sectors including: Biotechnology & Healthcare; Sustainable Technology & Consumer Products; Education; Sports & Entertainment; and Finance to help them gain access throughout the globe.
Brewer and Associates is headquartered in Minneapolis, MN and focuses on Global Business Development; Events, Road Shows & Logistics; and Marketing & Public Relations.
The Brewer Group Conference:
June 19, 2015, 9:00am - 5:00pm
Beyond Biotech: New Areas Investors Can Profit from in Life Sciences
TLSR: Are there any new developments in the Alzheimer's space?
PH: Biogen released promising Phase 1 data in March for its anti-amyloid monoclonal antibody, aducanumab, which could drive further R&D and biotech pharma investment into treatments for Alzheimer's. Amarantus BioScience Holdings Inc. (AMBS) stands to benefit from increased R&D in the Alzheimer's space. It is developing a blood-based biomarker test called LymPro to more easily diagnose patients with Alzheimer's.
LymPro evaluates the presence of a cell surface marker called CD69 on blood lymphocytes following a mitosis-promoting stimulus. LymPro works on the basis that if the cellular machinery is working correctly, CD69 will be upregulated following the stimulation of lymphocyte cells. However, if CD69 is not upregulated, cellular division dysfunction is likely the result, and Alzheimer's disease is more likely. Amarantus' studies show a decent correlation in this regard, and the company is looking to market LymPro to biopharmas developing Alzheimer's drugs in clinical trials.
TLSR: What is the benefit of early diagnosis?
PH: The idea is to better differentiate those patients who have early or medium stages of the disease versus those who do not. The process is helpful because by the time patients are enrolled in trials, the state of their disease may be too far advanced for an experimental treatment to have an effect. If LymPro can help better identify patients at earlier stages of disease, a wider window will open for an experimental therapy to potentially show a benefit versus placebo.
LymPro has received clearance for investigator use in clinical trials. Amarantus is working on obtaining the approvals that will be needed for it to be used as a diagnostic in primary care and broader medical settings.
TLSR: Does Amarantus have any other products in the pipeline?
PH: Amarantus is developing eltoprazine, which is a small molecule, 5-HT1A/1B serotonin receptor partial agonist. The drug is in Phase 2 development for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.
Levodopa is one of the most commonly used treatments for Parkinson's, but after five to 10 years, many patients experience random involuntary movements. Eltoprazine aims to treat the dyskinesia by dampening excess dopamine release, and it has already shown positive efficacy versus placebo in a Phase 2a trial with more than 200 patients. Amarantus recently started a 60-patient, Phase 2b study, and the data could be available next year. That could open up partnership opportunities.
The Parkinson's Disease Foundation estimates that more than 1M people have Parkinson's disease, and about half of them will develop dyskinesia. There is definitely a fair market for this type of drug.
You can use: MarketWatch
Was $6.90 and now $8.10
To Sponsors is a really good thing that AMBS is doing. I really believe that AMBS will be huge. Just need to have patience.
The CEO did say it.
(LD Micro) SNNLive will speak with Gerald Commissiong. He might.
I hope the conference will provide us good news!
Today, LD Micro Invitational Presentation & Webcast - 1:30 p.m. EDT / 10:30 a.m. PDT
Why do you keep saying $109? It is $109.000. On top of it, it says in thousands.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10713112
On the otcmarkets, it did say OTCQB and then changed into Pink and back to OTCQB. They made a mistake. Amarantus BioScience is OTCQB
Sounds good!
There is nothing wrong in guessing. Why can't we feel good about AMBS?
You can believe whatever you want. I have patience and really believe in AMBS!
That is why Jason Napodano hope the deal closes soon.
That is not true. They own ESS.
I totally agree!
Management to host conference call and webcast on Wednesday, May 27, 2015 at 5:00 p.m. EDT.
Alzheimer's Assoc. 4h4 hours ago
Discusses toll Alzheimer's will take on U.S. economy w/out more research funding. #NIHCaucus #ENDALZ
Click here : Alzheimer's Association
Marcum Microcap Conference Presentation on May 28, 2015, at 2:30 p.m. EDT / 11:30 a.m. PDT-
2 Conferences on May 28, 2015: 2015 Marcum Microcap Conference and SEETHRUEQUITY 4TH ANNUAL MICROCAP INVESTOR CONFERENCE
Yes I agree! Also partnerships would be nice.
It should go more than 6 cents today. GLTA!
"Advancing MANF, our first internally-discovered therapeutic product candidate, into human clinical studies will be a major advancement for the Company. Rapid production of MANF in collaboration with Catalent will enable us to achieve this objective as quickly and in the most cost-effective manner possible. The Company is currently targeting the orphan ocular indication retinitis pigmentosa (RP) for first-in-man studies, expected to start in 2016.
The project will utilize Catalent's proprietary GPEx® technology, which creates high-expression, extremely stable cell lines with speed and efficiency, typically capable of getting drug development projects to clinic in one-third the time of traditional approaches. The advantages of applying GPEx® technology span from early feasibility studies, to clinical manufacturing and commercial scale production.
About Catalent:
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.
Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
AMBS is moving forward in growth mode. They are currently undervalued.
Thanks for letting me know.
My Pick $AMBS
My 2nd choice $TTNP
Two Conferences:
SEETHRUEQUITY 4TH ANNUAL MICROCAP INVESTOR CONFERENCE New York City on May 28, 2015 8am - 6pm
AAIC>.15 Alzheimer's Association International Conference July 18-23, 2015 - Washington, D.C. United States
Yes, I agree! Wow! Alzheimer's Association International Conference! Sounds Good!